Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RSLS
Upturn stock ratingUpturn stock rating

ReShape Lifesciences Inc (RSLS)

Upturn stock ratingUpturn stock rating
$2.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: RSLS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1

1 Year Target Price $1

Analysts Price Target For last 52 week
$1Target price
Low$2.23
Current$2.44
high$414.7

Analysis of Past Performance

Type Stock
Historic Profit -26.54%
Avg. Invested days 69
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.89M USD
Price to earnings Ratio 0.01
1Y Target Price 1
Price to earnings Ratio 0.01
1Y Target Price 1
Volume (30-day avg) 1
Beta 1.94
52 Weeks Range 2.23 - 414.70
Updated Date 06/30/2025
52 Weeks Range 2.23 - 414.70
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 260.86

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -48.26%
Operating Margin (TTM) -165.23%

Management Effectiveness

Return on Assets (TTM) -53.5%
Return on Equity (TTM) -120.16%

Valuation

Trailing PE 0.01
Forward PE -
Enterprise Value 3412882
Price to Sales(TTM) 0.82
Enterprise Value 3412882
Price to Sales(TTM) 0.82
Enterprise Value to Revenue 0.48
Enterprise Value to EBITDA -0.02
Shares Outstanding 2385960
Shares Floating 737812
Shares Outstanding 2385960
Shares Floating 737812
Percent Insiders 10.63
Percent Institutions 0.73

Analyst Ratings

Rating 1
Target Price 1
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ReShape Lifesciences Inc

stock logo

Company Overview

overview logo History and Background

ReShape Lifesciences Inc., formerly known as EnteroMedics, was founded in 2002. Initially focused on neuromodulation for weight loss, the company transitioned to gastric balloon technology. Key milestones include FDA approvals and commercial launches of its products. The company has evolved its strategies and product offerings over the years.

business area logo Core Business Areas

  • Gastric Balloon Technology: ReShape Lifesciences Inc. develops and commercializes medical devices used in the treatment of obesity. Its main product line features intragastric balloons that help patients lose weight by occupying space in the stomach, promoting satiety, and reducing food intake.
  • ReShapeCare Virtual Weight Management Program: This program provides virtual support to patients undergoing weight loss procedures, including counseling, diet plans, and exercise guidance.

leadership logo Leadership and Structure

The company is led by a management team with expertise in medical devices and the treatment of obesity. The organizational structure includes departments for research and development, sales and marketing, operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ReShape Balloon: The ReShape Balloon is a dual intragastric balloon system designed to facilitate weight loss. Competitors include Apollo Endosurgery (NYSE: APEN) (now Boston Scientific), and Medtronic (MDT) with their respective intragastric balloon offerings. Limited market share data is available publicly. The company previously reported revenue from this product but has undergone restructuring.
  • ReShapeCare: A virtual weight management program designed to support patients using ReShape's weight loss devices or other weight management solutions. This provides ongoing guidance and support through lifestyle changes. Competitors include various telehealth weight management programs offered by companies like WW International (WW) and Ro.

Market Dynamics

industry overview logo Industry Overview

The obesity treatment market includes lifestyle changes, medical devices, pharmaceuticals, and surgical procedures. The market is driven by the increasing prevalence of obesity and related health conditions.

Positioning

ReShape Lifesciences Inc. focuses on providing less-invasive alternatives to bariatric surgery through its gastric balloon technology and virtual weight management programs. Its competitive advantage lies in its proprietary technologies and patient support programs.

Total Addressable Market (TAM)

The global obesity management market is projected to reach hundreds of billions of dollars. ReShape is positioned within the medical device and virtual care segments, with the potential to capture a portion of this large market through its innovative solutions.

Upturn SWOT Analysis

Strengths

  • Innovative gastric balloon technology
  • ReShapeCare virtual weight management program
  • Focus on less-invasive obesity treatment options
  • Experienced management team in medical devices
  • Intellectual property protection

Weaknesses

  • Limited market share compared to larger competitors
  • Financial instability
  • Historical losses
  • High operating costs
  • Reliance on regulatory approvals for new products

Opportunities

  • Expanding the product line to include additional weight management solutions
  • Partnerships with healthcare providers and insurers
  • Geographic expansion into new markets
  • Increasing awareness of less-invasive obesity treatments
  • Further development of ReShapeCare platform

Threats

  • Competition from established medical device companies
  • Regulatory hurdles and changing reimbursement policies
  • Adverse clinical trial results
  • Economic downturn impacting consumer spending on elective procedures
  • Technological advancements that could render existing products obsolete

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • BSX
  • WW

Competitive Landscape

ReShape Lifesciences Inc. faces intense competition from larger, more established medical device companies. It differentiates itself through its focus on less-invasive procedures and patient support programs. However, its limited financial resources pose a challenge.

Growth Trajectory and Initiatives

Historical Growth: The company's historical growth has been inconsistent, with periods of rapid growth followed by declines due to various factors, including market conditions and regulatory challenges.

Future Projections: Future growth projections are uncertain and depend on the successful commercialization of new products and the expansion of the ReShapeCare program. Analyst estimates are not widely available due to the company's small market capitalization.

Recent Initiatives: Recent initiatives include focusing on expanding the reach of ReShapeCare and strategic partnerships to broaden their market presence.

Summary

ReShape Lifesciences is a small player in the obesity treatment market with innovative technology. However, its financial instability, limited market share, and dependence on regulatory approvals pose significant challenges. Success hinges on successful commercialization efforts and effective management of resources, especially in the face of strong competitors. ReshapeLifesciences must look to capitalize on the growing market for weight loss solutions.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Industry reports
  • Press releases
  • Third-party financial data providers

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ReShape Lifesciences Inc

Exchange NASDAQ
Headquaters Irvine, CA, United States
IPO Launch date 2007-11-15
CEO, President & Director Mr. Paul F. Hickey
Sector Healthcare
Industry Medical Devices
Full time employees 17
Full time employees 17

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.